Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002697 | 0.93 | CA2 (0.52) | CA2CA1CA9MGLLL3MBTL1 | |
| SCHEMBL1621831 | 0.86 | CA2 (0.55) | CA2CA1CA9MGLLTSHR | |
| SCHEMBL31061188 | 0.83 | MGLL (0.48) | CA2CA1CA9MGLLL3MBTL1 | |
| SCHEMBL22070850 | 0.83 | MGLL (0.48) | CA2CA1CA9MGLLL3MBTL1 | |
| SCHEMBL23461748 | 0.83 | CA2 (0.52) | CA2CA1CA9MGLLTSHR | |
| Hydrochloric Acid SCHEMBL28277924 | 0.82 | MGLL (0.47) | MGLLL3MBTL1TDP1TSHREPHX2 | |
| SCHEMBL9011734 | 0.82 | TSHR (0.67) | L3MBTL1TDP1TSHREPHX2LTA4H | |
| SCHEMBL9011624 | 0.82 | TSHR (0.67) | L3MBTL1TDP1TSHREPHX2LTA4H | |
| SCHEMBL9011646 | 0.82 | TSHR (0.67) | L3MBTL1TDP1TSHREPHX2LTA4H | |
| SCHEMBL9011715 | 0.82 | TSHR (0.67) | L3MBTL1TDP1TSHREPHX2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CA2 363/4885CA1 961/4885CA9 582/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CA2 363/4885CA1 961/4885CA9 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.